Ifinatamab deruxtecan
 | |
| Clinical data | |
|---|---|
| Other names | DS-7300 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ifinatamab deruxtecan (DS-7300) is an experimental anti-cancer treatment developed by Merck and Daiichi Sankyo. It is an antibody–drug conjugate that "consists of an anti-B7-H3 antibody linked with a DNA topoisomerase I inhibiting anti-tumor agent".[1][2]
References
[edit]- ^ Katsumata, Len; Deguchi, Tsuneo; Hasegawa, Jun; Yamato, Michiko; Nishiya, Yumi; Watanabe, Akiko; Honda, Tomoyo; Minami, Megumi; Kasanuki, Naomi; Maejima, Takanori; Muramatsu, Sumie; Herrmann, Monika; Schulte, Nina; Polier, Gernot; Wang, Xuya; Yoshida, Takanori; Izumi, Nanae; Qian, Xiaozhong; Agatsuma, Toshinori; Nakamaru, Kenji (4 April 2023). "Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization". Cancer Research. 83 (7_Supplement): 4891. doi:10.1158/1538-7445.AM2023-4891. S2CID 259620618.
- ^ Patel, M.R.; Doi, T.; Koyama, T.; Falchook, G.S.; Friedman, C.F.; Piha-Paul, S.A.; Gutierrez, M.; Awad, M.M.; Mattour, A.H.; Satoh, T.; Okamoto, N.; Singh, J.; Yoshizuka, N.; Qian, M.; Qian, X.; Tran, B.P.; Dosunmu, O.; Lu, P.; Johnson, M.L. (October 2023). "690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study". Annals of Oncology. 34: S481–S482. doi:10.1016/j.annonc.2023.09.1876. S2CID 264385889.